言語を選択

IFN-alpha 2b

IFN-alpha 2b 詳細

英語名	Interferon alpha-2	市販薬剤の数	1
治験薬の数	10	ターゲットの別称	IFNA2B，IFNA2C，LeIF A，Interferon alpha-2，IFN-alpha-2，IFNA2，Interferon Alpha 2，Alpha-2a Interferon，Interferon Alpha 2b，Interferon Alpha A，Interferon Alpha 2a，Interferon Alpha-A，IFN-AlphaA，IFNA2A，INFA2，IFNA
研究＆開発段階	Approved

英語名	Interferon alpha-2
ターゲットの別称	IFNA2B，IFNA2C，LeIF A，Interferon alpha-2，IFN-alpha-2，IFNA2，Interferon Alpha 2，Alpha-2a Interferon，Interferon Alpha 2b，Interferon Alpha A，Interferon Alpha 2a，Interferon Alpha-A，IFN-AlphaA，IFNA2A，INFA2，IFNA
市販薬剤の数	1
治験薬の数	10
研究＆開発段階	Approved

IFN-alpha 2b 製品リスト

属性
Protein (2)
製品ライブラリ
オンライン (2)
種
Human (2)
タグ
Fc Tag (1)His Tag & Avi Tag (1)
マーカー
Unconjugated (1)Biotin-labeled (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
IFB-H5253	Human	HEK293	Human IFN-alpha 2b Protein, Fc Tag (MALS verified)
IFB-H82E3	Human	HEK293	Biotinylated Human IFN-alpha 2b Protein, His,Avitag™ (MALS verified)

総数量2

IFN-alpha 2bバックグランド

IFN-alpha is a cytokine that has an immunomodulatory function. It plays an important role not only in antiviral activity but also in several physiologic functions, such as activation of dendritic cells and accelerated expression of major histocompatibility complex I and II molecules that may cause increased antigen presentation. Variants of human leukocyte interferon alpha 2 (IFN-alpha 2a, alpha 2b, and alpha 2c) differ from each other by changes in their coding regions at nucleotide positions 137 and 170. IFN-alpha 2b (IFNα-2b) is an important cytokine and used for antiviral and anticancer treatment.

IFN-alpha 2b分子の別称

IFN-alpha 2b,IFNA2B,IFN-alpha 2 (alpha 2b),interferon alpha 2b

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Autologous CD34+-enriched hematopoietic stem and progenitor cells (Genenta Science)		Phase 2 Clinical	Genenta Science Srl	Carcinoma, Renal Cell; Glioblastoma; Multiple Myeloma	詳細
NG-641	EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAP	Phase 1 Clinical	Akamis Bio Ltd	Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Squamous Cell Carcinoma of Head and Neck	詳細
recombinant human serum albumin-interferon-alpha-2a fusion protein (Qilu Pharmaceutical)		Phase 1 Clinical	Qilu Pharmaceutical Co Ltd	Hepatitis B	詳細
Q101-pegylated interferon alfa-2a (CSPC Zhongqi Pharmaceutical Technology)		Phase 1 Clinical	CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd	Hepatitis B, Chronic	詳細
PEGylated interferon alpha-1b (Shanghai Institute of Biological Products)		Phase 1 Clinical	Shanghai Institute of Biological Products Co Ltd	Hepatitis B; Neoplasms; Varicella Zoster Virus Infection	詳細
SFR-1882	SFR-1882	Phase 1 Clinical	Tianjin Sinobiotech Ltd	Anemia; Renal Insufficiency	詳細
CX-801	CX-801	Phase 1 Clinical	Cytomx Therapeutics Inc	Carcinoma, Renal Cell; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck	詳細
ORB-011	ORB-011	Phase 1 Clinical		Neoplasms; Solid tumours	詳細
interferon alfa-2b follow-on biologic (Amoytop)		Clinical	Xiamen Amoytop Biotech Co Ltd	Condylomata Acuminata; Hepatitis B; Hepatitis C; Leukemia, Hairy Cell; Lymphoma, Follicular; Melanoma; Sarcoma, Kaposi	詳細
interferon-alpha2b (The University Health Network)		Clinical	University Health Network (Uhn)	Coronavirus Disease 2019 (COVID-19)	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Nadofaragene firadenovec	SCH-721015; FE-999326; SCH-209702/SCH-721015; SCH-721015/SCH-209702; TR-002	Approved	Fkd Therapies, Schering-Plough Labo Nv	Instiladrin, Adstiladrin	United States	Urinary Bladder Neoplasms	Ferring Pharmaceuticals A/S	2022-12-16	Adenocarcinoma; Carcinoma, Transitional Cell; Mesothelioma; Pancreatic Neoplasms; Solid tumours; Urinary Bladder Neoplasms	詳細